SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer

Plans to initiate a pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT) Follows €37 M Series A investment to progress emactuzumab, a potentially best-in-class CSF-1R antibody licensed on an exclusive, worldwide basis from Ro... Biopharmaceuticals, Oncology, Personnel SynOx Therapeutics, emactuzumab, Tenosynovial Giant Cell Tumours
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news